On the other hand, miR-133a-3p was demonstrated to reduce osteolytic bone lesions in PCa in vivo via downregulation of the PI3K/AKT signaling pathway, directly targeting multiple cytokine receptors, such as epidermal growth factor receptor (EGFR), fibroblast growth factor receptor 1 (FGFR1), insulin-like growth factor1 receptor (IGF1R), and MET receptor tyrosine kinase [119]. This evidence concerns the gene EGFR and posterior cortical atrophy.